Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan;
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Anticancer Res. 2021 Dec;41(12):6211-6216. doi: 10.21873/anticanres.15440.
BACKGROUND/AIM: Recently, trifluridine/tipiracil (FTD/TPI) treatment was established as a later-line treatment for metastatic colorectal cancer (mCRC). However, FTD/TPI treatment is frequently associated with hematological toxicity. The aim of this study was to evaluate the efficacy and safety of FTD/TPI in elderly patients with mCRC in a real-world setting.
We retrospectively reviewed the medical records of 74 patients with mCRC who were treated with FTD/TPI.
The treatment effect of the elderly patient group was not inferior to that of the younger patient group. Although the incidence of hematological toxicity in the elderly patient group was higher than that in the younger patient group, there were no significant differences in the rate of treatment discontinuation due to adverse events between the two groups.
In elderly patients with mCRC, FTD/TPI treatment was effective for prolonging survival. However, it should be noted that elderly patients showed a higher rate of hematological toxicity than younger patients.
背景/目的： 最近，替比氟尿苷/盐酸拓扑替康（FTD/TPI）治疗被确立为转移性结直肠癌（mCRC）的二线治疗方法。然而，FTD/TPI 治疗常伴有血液学毒性。本研究旨在评估 FTD/TPI 在真实世界环境下治疗老年 mCRC 患者的疗效和安全性。
我们回顾性分析了 74 例接受 FTD/TPI 治疗的 mCRC 老年患者的病历。
老年患者组的治疗效果并不逊于年轻患者组。尽管老年患者组血液学毒性的发生率高于年轻患者组，但两组因不良反应而停止治疗的比例无显著差异。
在老年 mCRC 患者中，FTD/TPI 治疗可有效延长生存期。然而，应注意老年患者的血液学毒性发生率高于年轻患者。
